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khartsho@bu.eduThe most terrifying aspect of pandemic inﬂuenza A infection
is its ability to cause respiratory failure and death in young
adults. There is a major debate in the literature regarding
whether such severe outcomes result from more robust viral
infection in the lung and associated cellular injury or from
lung injury caused by a pathogenic immune response to some
extent uncoupled from viral replication (eg, cytokine storm).
The article by Gao et al1 in this issue makes useful contri-
butions in this regard. The authors made use of an important
resource of lung tissue obtained from 48 subjects who died
of infection with the 2009 H1N1 pandemic virus (2009
pH1N1). Although the pandemic did not result in such
massive death and morbidity as was caused by the 1918
H1N1 pandemic, it was clearly associated with a disturbing
incidence of pneumonia and respiratory death in young
adults.2 In the group reported by Gao et al,1 the mean age was
37.33 years. As in other inﬂuenza A pandemics and seasonal
epidemics,3 a signiﬁcant proportion of the deaths in 2009
were associated with bacterial superinfection (28%). There
was a relatively high incidence (68%) of underlying medical
conditions in this cohort of patients, including factors known
to predispose to more severe inﬂuenza infection, such as
asthma, obesity, pregnancy, or immunosuppression.
An important ﬁnding in these fatal cases was the demon-
stration of protracted viral replication in lung tissue. Notably,
the viral load was positively correlated with duration of
illness and with elevated levels of some key proinﬂamma-
tory cytokines in the lung (ie, MIP-1b, MCP-1, IP-10, and
RANTES). Other proinﬂammatory cytokines were also
elevated, although these were not correlated with viral load.
Of interest, however, was the signiﬁcantly greater elevation
of IL-6 and TNF-a in patients who had bacterial superin-
fection. Other researchers have shown an association of
severe outcomes with 2009 pH1N1 in humans with high
serum levels of IL-6,4 although these studies did not assess
the association of viral load or bacterial superinfection with
cytokine induction. The association between viral replication
and expression of proinﬂammatory cytokines was furtherCopyright ª 2013 American Society for Investigative Pathology.
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http://dx.doi.org/10.1016/j.ajpath.2013.06.020substantiated by pathological analysis showing that viral
antigen and cytokine expression occurred in the same areas
of the lung.
An additional important ﬁnding of the Gao et al1study is
a marked elevation of Fas ligandmRNA and a decrease in Fas
antigen mRNA in patient lungs, compared with controls.
Thus, there was an imbalance between the levels of Fas ligand
and Fas antigen. The Fas ligand levels also positively corre-
lated with viral load. Pathological studies conﬁrmed the
presence of extensive apoptosis in areas of viral infection.
Overall, the ﬁndings of Gao et al1 support the concept of
linkage among sustained viral infection, immune response,
and cellular damage.
Intrinsic Differences in Pathogenicity between
Pandemic and Seasonal Inﬂuenza A Strains
Seasonal inﬂuenza A epidemics are also associated with
mortality, which can be substantial if the current vaccine
does not closely match the prevalent viral strain. Seasonal
epidemics cause mortality predominantly in the elderly and
very young. So what makes pandemic inﬂuenza different,
and why does it cause more mortality in young adults? One
key factor separating pandemic and seasonal inﬂuenza A is
the greater intrinsic pathogenicity of pandemic strains. The
1918 H1N1 is particularly notable in this regard; it is highly
lethal in a variety of animal models, because of increased
replication and profound inﬂammatory pathology in the
lung.5 Similarly, 2009 pH1N1 causes increased weight loss
and mortality in ferrets, compared with recent seasonal H1N1
strains.6 The ferret model is frequently used in inﬂuenza
studies because it appears to mirror human infection more
Hartshornclosely than do mouse models. It should be noted that the
increased pathogenicity of 2009 pH1N1 is less profound than
that of the 1918 virus, consistent with the far greater death toll
caused by the 1918 virus.
Reverse genetics is a powerful virological technique now
extensively used in inﬂuenza studies. This technique allows
construction of novel viruses from plasmids containing intact
or mutated versions of the eight genome segments of inﬂu-
enza A viruses. With this method, it has been possible to
speciﬁcally identify the role of the viral hemagglutinin (HA)
or other viral genes in inﬂuenza pathogenesis. To some
extent, the immune pathology and increased viral replication
of the 1918 virus can be dissociated using a reverse genetics
approach.5 The inﬂammatory pathology and mortality relate
largely to properties of the 1918 HA molecule, whereas the
increased viral replication involves the distinct properties of
the polymerase complex. Similarly, HA of other pandemic
viruses [eg, 1957 (H2), 1968 (H3), or 2009 (H1)] directly
contributes to the greater illness and pathology of these
viruses in mice, compared with seasonal inﬂuenza.7
Glycosylation of HA appears to be an important deter-
minant of pathogenicity. Viruses containing just the HA of
the pandemic strains combined with gene segments of
seasonal H1N1 are resistant to inhibition by surfactant
protein D, because of minimal glycosylation of the head
region of HA.7,8 Surfactant protein D plays an important role
in initial containment of inﬂuenza.9 Other innate immune
inhibitors are also inactive against pandemic H1N1.8 Thus,
the ability of pandemic inﬂuenza to bypass components of
the innate response could contribute to pathogenesis. Other
properties of 2009 pH1N1 also contribute to greater patho-
genicity, compared with seasonal H1N1 (eg, the ability to
suppress activation of retinoid-inducible gene 1 protein and
consequently interferon responses).10Differences in Host Response to Pandemic
Inﬂuenza A Strains
Differences in host responsiveness to inﬂuenza virus likely
also account for differences in disease severity. Newly
weaned ferrets were shown to have less disease severity than
adult animals infected with pandemic H1N1 of 2009.11 In this
case, viral replication did not differ between the young and
adult animals, but the young exhibited reduced disease
severity and pulmonary pathology, because of more robust
interferon and IL-10 responses. This might account for the
observation of relatively less severe clinical symptoms among
pediatric patients during the 2009 pandemic.11 In contrast,
pregnantwomenwere particularly vulnerable during the 2009
H1N1 pandemic. A pregnant mouse model demonstrated
increased severity of infection with 2009 pH1N1 and linked
the increased severity to pathogenic immune responses and
not to increased viral replication.12 Pregnantwomenwere also
shown to have reduced interferon responses during the 2009
pH1N1 pandemic.13 These two ﬁndings are not necessarily1126incompatible, because failure of the initial type 1 interferon
response could result in more damaging secondary innate
responses.14 A useful paradigm in evaluating the innate
response to inﬂuenza A virus is that there are initial defense
factors that may be able to contain or down-regulate infection
at the outset. These would include interferons produced by
airway epithelial cells and soluble inhibitors such as surfac-
tant proteins or anti-microbial peptides. If the virus succeeds
in bypassing these constraints, then a more costly inﬂamma-
tory response must occur to contain the virus.
Differences in Prior H1N1 Exposure among
Elderly and Young Adults
Another key factor in determining disease severity in
different age cohorts is the history of prior exposure to related
viral strains. For instance, elderly people were less affected
during the 1918 and 2009 pandemics, probably because of
retention of cross-reactive neutralizing antibodies from
remote H1N1 exposure.15 It does not appear that 2009
pH1N1 was intrinsically less pathogenic in the elderly.
Elderly macaques had both increased viral load and more
severe innate immune pathology in response to this virus.16
Based on mouse models,17 a compelling hypothesis has
been advanced that increased illness in young adults infected
with 2009 pH1N1 relates to lack of adequate neutralizing
antibody protection, despite a robust cell-mediated response.
According to this hypothesis, young adults exposed only to
the highly glycosylated HA of seasonal H1N1 strains from
1977 to 2008 had poor antibody protection against the less
glycosylated 2009 pH1N1. In contrast, the cell-mediated
response to inﬂuenza is determined by conserved internal
viral proteins, such as polymerase and nucleoproteins. Thus,
the same subjects had robust cell-mediated response to the
pandemic strain, perhaps contributing to lung injury. Older
subjects who retained antibody responses to H1N1 strains
from 1918 through 1957 (when H1N1 strains were replaced
by H2N2) were able to effectively neutralize the 2009 strain.
Conclusions
Clearly, the innate and adaptive immune responses to inﬂu-
enza A virus are highly complex. It is extraordinary that an
apparently genetically limited virus has somany effects on the
human population and on human immune responses. One
obvious factor in the success of inﬂuenza A viruses is the
existence of animal reservoirs, which allow for exchange of
whole genome segments between human and animal strains.
In addition, the virus appears to make maximum use of its
limited genomic repertoire. Recently, it has become clear that
alternative reading frames allow the virus to encode additional
proteins that modulate the host response,18 such that there
are now 13 deﬁned gene products for inﬂuenza. In addition,
the viral proteins interact with an extraordinary number of
host proteins, leading to pleomorphic effects on the hostajp.amjpathol.org - The American Journal of Pathology
Commentaryresponse.19 One need only look at the viral NS1 protein,
which suppresses innate antiviral responses on many levels,
including inhibition of type 1 interferon production, inhibi-
tion of action of interferon-related genes (eg, protein kinase R
and oligoadenylate synthetase), and inhibition of PI-3 kinase
and RIG-1 activation (among many other activities).20
It is obvious from this cursory review of the massive
literature on inﬂuenza A virus infection that many factors are
involved in determining pandemic inﬂuenza severity, and
that animal model systems support a role both for increased
replication potential of these viruses and for increased ability
to trigger potentially pathogenic immune responses. The
ﬁndings of Gao et al1 cannot address the issue of which of
these two aspects is more responsible for pandemic inﬂuenza
Aeassociated mortality. Their study does, however, provide
valuable human data and overall lends support to the
contention that proinﬂammatory cytokine generation and
lung injury are closely linked to sustained viral replication in
the lungs of fatal cases. From their ﬁndings, it would seem
that efforts to improve vaccine delivery and effectiveness and
antiviral therapies should continue to take precedence over
inhibition of pathogenic immune responses. Increasing
knowledge of the contributions of speciﬁc viral genes to
pathogenesis should allow for novel antiviral strategies.References
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